Sibel Health Wearable Sensor Gains FDA Nod
Sibel Health's Aria wearable sensor has received FDA acceptance for COA (Clinical Outcome Assessment) qualification, supported by over $1M in funding. The device, which attaches to the suprasternal notch, allows for continuous, non-invasive monitoring of vital signs. This development could enable more granular data collection for insurance risk scoring and remote claims assessment.
- Sibel Health was founded in 2018 as a spin-out from Northwestern University by physician-engineer Dr. Steve Xu, who currently serves as the company's CEO. - The Aria sensor uses acousto-mechanic sensing to detect coughs via mechanical vibrations and acoustic signatures, specifically avoiding frequencies used in audible speech to ensure user privacy. An accompanying AI algorithm automates the detection of cough events, eliminating the need for manual data labeling. - This is Sibel Health's third device to be accepted into the FDA's Clinical Outcome Assessment (COA) Qualification Program; as of February 12, 2026, the company is responsible for three of the eight total digital health technologies ever accepted into the program. - The company's other FDA-accepted technologies include a sensor for monitoring scratching in atopic dermatitis and another for tracking swallowing in patients with Parkinson's disease. - Sibel Health has raised over $100 million in total funding, with investors including The Steele Foundation for Hope, Dräger, Samsung Next, and the Gates Foundation. - Beyond the Aria sensor for respiratory conditions, Sibel's core platform, ANNE One, is FDA-cleared for ICU-grade, wireless monitoring of a range of vital signs for neonatal, maternal, and adult care. - Data from wearables is being explored by insurers like Munich Re and Hannover Re to potentially enhance risk models beyond traditional metrics by incorporating real-time lifestyle data, such as activity levels and sleep patterns, to create more individualized policies.
